2024
Real‐world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer
Sukumar J, Sardesai S, Ni A, Williams N, Johnson K, Quiroga D, Ramaswamy B, Wesolowski R, Cherian M, Stover D, Gatti‐Mays M, Pariser A, Sudheendra P, George M, Lustberg M. Real‐world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer. Cancer Medicine 2024, 13: e7317. PMID: 38895891, PMCID: PMC11185945, DOI: 10.1002/cam4.7317.Peer-Reviewed Original ResearchConceptsOvarian suppressionEndocrine therapyAdjuvant endocrine therapyBreast cancerClinicopathological featuresAromatase inhibitorsOS useHR+/HER2+ breast cancerOptimal adjuvant endocrine therapyHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Real-world treatment patternsCohort of premenopausal womenAnti-HER2 therapyPremenopausal breast cancerClinicopathological risk factorsMultivariable logistic regression assessed associationsLogistic regression assessed associationsPremenopausal BCPrescribed tamoxifenPremenopausal patientsPremenopausal womenBC subtypesContemporary cohortAnti-HER2Long-Term Considerations for Young Breast Cancer Patients: Fertility, Sexual Health, and Quality of Life
Proussaloglou E, Lustberg M. Long-Term Considerations for Young Breast Cancer Patients: Fertility, Sexual Health, and Quality of Life. Current Breast Cancer Reports 2024, 16: 227-236. DOI: 10.1007/s12609-024-00548-z.Peer-Reviewed Original ResearchYoung breast cancer patientsSurvivorship careBreast cancer patientsEffectiveness of cancer careFamily planning concernsPost-partum careUnique survivorship needsQuality-of-life issuesBreast cancerQuality of lifeCancer patientsSurvivorship needsGenitourinary syndrome of menopauseCancer careDisease-free recurrenceAnti-estrogen therapyUnique group of patientsSexual healthGroup of patientsCareVaginal estrogenEndocrine therapyOverall survivalSummaryAdditional researchIatrogenic menopauseEyebrow and Eyelash Loss in Patients With Cancer.
Rose L, Khuhro A, Minta A, Novice M, Novice T, Lustberg M, Ruddy K, Rake E, Loprinzi C, Dulmage B. Eyebrow and Eyelash Loss in Patients With Cancer. Journal Of Drugs In Dermatology 2024, 23: 327-331. PMID: 38709698, DOI: 10.36849/jdd.8003.Peer-Reviewed Original ResearchConceptsPrevention optionsRadiation therapyTopical vasoconstrictorEndocrine therapyEyelash lossTreatment optionsPrescription medicationsCancer treatmentPatientsScalp coolingHair lossRobust researchMadarosisPermanent tattoosTherapyCancerTreatmentEyebrowsEyelash hairScalpOptionsChemotherapyCryotherapyVasoconstrictorDermatologists
2023
Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in patients with breast cancer.
Minta A, Rose L, Park C, Trovato S, Lustberg M, Sudheendra P, Cherian M, Gatti-Mays M, Stover D, Wesolowski R, Sardesai S, Ramaswamy B, Williams N, Dulmage B. Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in patients with breast cancer. Journal Of Clinical Oncology 2023, 41: e13083-e13083. DOI: 10.1200/jco.2023.41.16_suppl.e13083.Peer-Reviewed Original ResearchBreast cancerEIA patientsDermatology referralsOnset of alopeciaRetrospective cohort studyMetastatic breast cancerRisk of alopeciaCyclin-dependent kinase 4Endocrine monotherapyOral minoxidilEndocrine therapyClinical improvementCohort studyRetrospective cohortFemale patientsTherapeutic optionsCombination therapyGrade severityTherapeutic responseFavorable outcomeAndrogenetic alopeciaDean scaleCDK4/6iPatientsSignificant improvementHair loss during and after breast cancer therapy
Rose L, Lustberg M, Ruddy K, Cathcart-Rake E, Loprinzi C, Dulmage B. Hair loss during and after breast cancer therapy. Supportive Care In Cancer 2023, 31: 186. PMID: 36826602, DOI: 10.1007/s00520-023-07634-5.Peer-Reviewed Original ResearchConceptsTreatment optionsHair lossDistressing side effectsChemotherapy-induced alopeciaCancer therapyBreast cancer therapyEndocrine therapyMajor surgeryPatient counselingTelogen effluviumBreast cancerBreast oncologistsSide effectsPrevention strategiesAlopeciaTherapyChemotherapyPatientsSurgeryOncologistsOptionsEtiologyCancer
2022
Right Sizing Systemic Therapy for Patients with Breast Cancer. Where are we Today?
Williams N, Grimm M, Gast K, Lustberg M. Right Sizing Systemic Therapy for Patients with Breast Cancer. Where are we Today? Current Breast Cancer Reports 2022, 14: 142-152. DOI: 10.1007/s12609-022-00463-1.Peer-Reviewed Original ResearchEarly-stage breast cancerBreast cancerSystemic therapyClinical outcomesER-positive breast cancerTriple-negative breast cancerBreast cancer supportRobust clinical outcomesOptimized clinical outcomesQuality of lifePersonalized medicine approachNeoadjuvant regimensAdditional therapyEndocrine therapySelect patientsClinical trialsBest therapyPrognostic biomarkerPatientsCancer supportTherapyMedicine approachCancerRoutine useGenomic testingThe mutational profile of ER-, PR+, HER2- metastatic breast cancer.
Fischbach N, Huang R, Lustberg M, Pelletier M, Pusztai L, Sivakumar S, Sokol E, Ross J, Levy M. The mutational profile of ER-, PR+, HER2- metastatic breast cancer. Journal Of Clinical Oncology 2022, 40: 1025-1025. DOI: 10.1200/jco.2022.40.16_suppl.1025.Peer-Reviewed Original ResearchTriple-negative breast cancerComprehensive genomic profilingMetastatic breast cancerBreast cancerClinical trialsPathology reportsMutational profileHER2- metastatic breast cancerConsecutive breast cancersAnti-estrogen therapyNegative breast cancerPD-L1 IHCPotential therapeutic implicationsHigh rateEndocrine therapyEstrogen therapyPatient ageFoundation MedicineKRAS alterationsRare subtypeHER2 expressionClinical behaviorReceptor phenotypeBreast carcinomaTreatment strategies
2021
Delay Discounting and Adjuvant Endocrine Therapy Adherence in Hormone Receptor-Positive Breast Cancer
Vaughn JE, Ammermann C, Lustberg MB, Bickel WK, Stein JS. Delay Discounting and Adjuvant Endocrine Therapy Adherence in Hormone Receptor-Positive Breast Cancer. Health Psychology 2021, 40: 398-407. PMID: 34323542, DOI: 10.1037/hea0001077.Peer-Reviewed Original ResearchConceptsEndocrine therapy adherenceTherapy adherenceHormone receptor-positive breast cancerAdjuvant endocrine therapy adherenceReceptor-positive breast cancerOral endocrine therapyBreast cancer survivorsBreast cancer patientsSelf-reported adherencePatient-centered factorsBrief behavioral interventionCross-sectional associationsPotential therapeutic targetMaladaptive health behaviorsEndocrine therapyMedication nonadherenceCancer survivorsCancer patientsRisk factorsBreast cancerTherapeutic targetHealth behaviorsPatientsBehavioral interventionsSurvivorsSurvival outcomes in patients with IDC and ILC breast cancer: A well matched single institution study.
Grimm M, Ramaswamy B, Lustberg M, Wesolowski R, Sardesai S, VanDeusen J, Cherian M, Stover D, Gatti-Mays M, Pariser A, Kassem M, Stephens J, Palettas M, Williams N. Survival outcomes in patients with IDC and ILC breast cancer: A well matched single institution study. Journal Of Clinical Oncology 2021, 39: e13056-e13056. DOI: 10.1200/jco.2021.39.15_suppl.e13056.Peer-Reviewed Original ResearchFirst-line endocrine therapyProgression-free survivalInvasive lobular carcinomaMedian progression-free survivalEndocrine therapyMedian overall survivalOverall survivalBreast cancerDuctal cancerLobular cancerEstrogen receptor/progesterone receptorMetastatic invasive lobular carcinomaOhio State University Comprehensive Cancer CenterDistinct clinicopathologic characteristicsInitial endocrine therapyInitiation of chemotherapyYear of diagnosisKaplan-Meier methodMetastatic breast cancerSite of metastasisInvasive breast cancerSingle-institution studyComprehensive cancer centerLine endocrine therapyConcerns of resistanceNeoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic
Park KU, Gregory M, Bazan J, Lustberg M, Rosenberg S, Blinder V, Sharma P, Pusztai L, Shen C, Partridge A, Thompson A. Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic. Breast Cancer Research And Treatment 2021, 188: 249-258. PMID: 33651271, PMCID: PMC7921279, DOI: 10.1007/s10549-021-06153-3.Peer-Reviewed Original ResearchConceptsAxillary lymph node dissectionNeoadjuvant endocrine therapyMedical oncologistsRadiation oncologistsOmission of ALNDEstrogen positive breast cancer patientsPositive breast cancer patientsEarly-stage breast cancerEndocrine therapy useMetastatic axillary diseaseLymph node dissectionBreast cancer patientsMultidisciplinary tumor boardStage breast cancerClinical trial organizationsPercent of practicesUS medical oncologistsCOVID-19 pandemicPre-pandemic timesRegional COVID-19 casesAxillary diseaseMicrometastatic nodesSurgery 2Endocrine therapyLocoregional management
2020
Applying the Collaborative Care Model to treat depression and anxiety in breast cancer (BC) patients.
Johns K, Kalister S, Mwandha N, Adams E, Basinger H, Fugett S, Crawford D, Draime M, Shinde N, Kassem M, Radcliff L, Unthank B, Cherian M, Sardesai S, Stover D, Vandeusen J, Wesolowski R, Williams N, Ramaswamy B, Lustberg M. Applying the Collaborative Care Model to treat depression and anxiety in breast cancer (BC) patients. Journal Of Clinical Oncology 2020, 38: e14004-e14004. DOI: 10.1200/jco.2020.38.15_suppl.e14004.Peer-Reviewed Original ResearchCollaborative care modelPHQ-9 scoresCare modelCancer patientsPHQ-9Satisfaction scoresAverage patient satisfaction scoreRegular case reviewBreast cancer patientsPatient satisfaction scoresGAD-7 scoresInitial scoresMental health servicesMental health careMental health resourcesTeam-based modelForms of cancerEndocrine therapyClinical suspicionExcess morbidityMedian ageMedical oncologistsBC patientsCDK4/6 inhibitorsCancer population
2019
CLO19-027: Assessment of Metastatic Invasive Lobular Carcinoma Management and Outcomes From 2004-2014: A Single Institution Experience
Boutrid H, Lustberg M, Vandeusen J, Sardesai S, Stover D, Wesolowski R, Cherian M, Stephens J, Palettas M, Morgan E, Kassem M, Berger M, Vargo C, Ramaswamy B, Williams N. CLO19-027: Assessment of Metastatic Invasive Lobular Carcinoma Management and Outcomes From 2004-2014: A Single Institution Experience. Journal Of The National Comprehensive Cancer Network 2019, 17: clo19-027. DOI: 10.6004/jnccn.2018.7251.Peer-Reviewed Original ResearchMetastatic invasive lobular carcinomaProgression-free survivalInvasive lobular carcinomaFirst-line treatment groupEndocrine therapyFirst-line treatmentOverall survivalCDK 4/6 inhibitorsMetastatic settingBone metastasesTreatment groupsMedian progression-free survivalOhio State University Comprehensive Cancer CenterInvasive breast cancer casesOnly bone metastasesMedian overall survivalFirst-line therapyWidespread metastatic diseaseKaplan-Meier methodRetrospective chart reviewSingle institution experienceInvasive ductal cancerKaplan-Meier curvesPreferred treatment optionAppropriate clinical context
2018
Fractional CO2 laser therapy for genitourinary syndrome of menopause (GSM) in survivors of breast cancer (BC).
Quick A, Zvinovski F, Hudson C, Hundley A, Evans C, Suresh A, Stephens J, Carpenter K, Ramaswamy B, Reinbolt R, Noonan A, VanDeusen J, Wesolowski R, Stover D, Williams N, Sardesai S, Smith K, Faubion S, Loprinzi C, Lustberg M. Fractional CO2 laser therapy for genitourinary syndrome of menopause (GSM) in survivors of breast cancer (BC). Journal Of Clinical Oncology 2018, 36: 202-202. DOI: 10.1200/jco.2018.36.34_suppl.202.Peer-Reviewed Original ResearchVaginal Assessment ScaleSerious adverse eventsFractional CO2 laser therapyCO2 laser therapyFemale Sexual Function IndexUrogenital Distress InventoryVaginal drynessBC survivorsBreast cancerLaser therapyStudy treatmentSingle-arm feasibility studySecondary efficacy endpointsFinal efficacy analysisSexual Function IndexER/PRFractional CO2 laser treatmentFractional CO2 laserEndocrine therapySham laserEfficacy endpointFSFI scoreAdverse eventsGenitourinary syndromePrimary efficacy
2015
Impact of breast cancer treatment on body mass index (BMI) over time.
Reinbolt R, Pan X, Wandell K, Pilarski R, Layman R, Mrozek E, Ramaswamy B, Wesolowski R, Lustberg M. Impact of breast cancer treatment on body mass index (BMI) over time. Journal Of Clinical Oncology 2015, 33: 94-94. DOI: 10.1200/jco.2015.33.28_suppl.94.Peer-Reviewed Original ResearchBody mass indexBreast cancer patientsEndocrine therapyAromatase inhibitorsWeight gainBMI changeCancer patientsEarly placebo-controlled trialsInitial body mass indexEarly-stage breast cancerHigher body mass indexBody mass index (BMI) changeBreast cancer patient cohortsPlacebo-controlled trialRetrospective chart reviewStage breast cancerBreast cancer treatmentCancer patient cohortsBreast cancer therapyQuality of lifeDifferent treatment groupsAI therapyChart reviewTreatment initiationMass indexPalbociclib
Mangini N, Wesolowski R, Ramaswamy B, Lustberg M, Berger M. Palbociclib. Annals Of Pharmacotherapy 2015, 49: 1252-1260. PMID: 26324355, PMCID: PMC7331461, DOI: 10.1177/1060028015602273.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCyclin-Dependent KinasesDisease-Free SurvivalEstradiolFemaleFulvestrantHumansLetrozoleNeoplasms, Hormone-DependentNitrilesPiperazinesPyridinesRandomized Controlled Trials as TopicReceptor, ErbB-2TriazolesUnited StatesConceptsProgression-free survivalAdvanced breast cancerInvestigator-assessed median progression-free survivalMedian progression-free survivalPhase III trialsBreast cancerEndocrine therapyIII trialsOncology abstractsHER2-negative advanced breast cancerHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Negative advanced breast cancerConfirmatory phase III trialClinical Oncology abstractsMedical Oncology abstractsPALOMA-3 trialFirst-line settingPhase II trialGrowth factor receptor 2Drug Administration approvalFactor receptor 2Life-threatening diseaseCyclin-dependent kinase 4Novel small molecule inhibitorAtrophic Vaginitis in Breast Cancer Survivors: A Difficult Survivorship Issue
Lester J, Pahouja G, Andersen B, Lustberg M. Atrophic Vaginitis in Breast Cancer Survivors: A Difficult Survivorship Issue. Journal Of Personalized Medicine 2015, 5: 50-66. PMID: 25815692, PMCID: PMC4493485, DOI: 10.3390/jpm5020050.Peer-Reviewed Original ResearchBreast cancer survivorsAtrophic vaginitisCancer survivorsEndocrine therapySelective estrogen receptor modulatorsSystemic estrogen therapyPatient-reported symptomsEstrogen receptor modulatorsVariety of symptomsQuality of lifeVaginal moistureEstrogen therapyLifestyle modificationLocal estrogenTopical estrogenVaginal drynessGynecological examinationSurvivorship issuesGenital skinOvarian failureVaginal dischargeSystematic therapyAromatase inhibitorsReceptor modulatorsBreast cancerEndocrine Therapy in Breast Cancer: The Neoadjuvant, Adjuvant, and Metastatic Approach
Reinbolt R, Mangini N, Hill J, Levine L, Dempsey J, Singaravelu J, Koehler K, Talley A, Lustberg M. Endocrine Therapy in Breast Cancer: The Neoadjuvant, Adjuvant, and Metastatic Approach. Seminars In Oncology Nursing 2015, 31: 146-155. PMID: 25951743, DOI: 10.1016/j.soncn.2015.02.002.Peer-Reviewed Original ResearchConceptsEndocrine therapyBreast cancerMetastatic breast cancer settingLong-term disease outcomesHormone-positive breast cancerBreast cancer settingPositive breast cancerNeoadjuvant therapyTherapy adherenceClinical guidelinesSymptom interventionCancer settingDisease outcomeClinical considerationsOptimal durationNursing practiceTherapyCancerAdditional researchPivotal roleTreatmentNational statisticsNeoadjuvantAdjuvantSymptoms